News

Two genes identified as VTE risk loci


 

References

A meta-analysis has identified two genes as susceptibility loci for venous thromboembolism, according to Marine Germain of the Institute for Cardiometabolism and Nutrition, Paris, and associates.

The identified risk loci were TSPAN15 and SLC44A2, with the odds ratios for VTE at 1.31 and 1.21, respectively. The most significant single-nucleotide polymorphism for the TSPAN15 loci was the intronic rs78707713; for SLC44A2, the most significant SNP was the nonsynonymous rs2288904, with ORs of 1.42 and 1.28, respectively. Although these associations are not strong, statistical evidence was much more convincing in the discovery and replication stages, the researchers reported.

“The identified VTE-associated SNPs map to genes that are not in conventional pathways to thrombosis that have marked most of the genetic associations to date, suggesting that these genetic variants represent novel biological pathways leading to VTE,” the investigators wrote.

Find the full study in the American Journal of Human Genetics (2015 April 2 [doi:10.1016/j.ajhg.2015.01.019]).

Recommended Reading

Genetic blood profiles can estimate risk levels of VTE patients
MDedge Cardiology
Venous thromboembolism common after heart transplant
MDedge Cardiology
Some VTE patients may receive anticoagulants for too long
MDedge Cardiology
Outcomes worse for lung cancer patients with VTE
MDedge Cardiology
Extended anticoagulant therapy reduced risk of VTE recurrence
MDedge Cardiology
PE patients with malignancy survived longer if given LMWH instead of oral VKA
MDedge Cardiology
For high-risk SVT patients, anticoagulants may be effective option
MDedge Cardiology
Few PE patients treated with catheter-directed interventions had complications
MDedge Cardiology
VTE with transient risk factors is being overtreated
MDedge Cardiology
Study: More DVTs than expected in patients who had varicose vein surgeries
MDedge Cardiology